Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

Completed · Phase 1/Phase 2

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by monoclonal antibody therapy used to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy plus peripheral stem cell transplantation in treating patients who have lymphoma or Waldenstrom's macroglobulinemia that has not responded to previous therapy.

Key facts

Study ID

NCT00004107

Run by

Garden State Cancer Center at the Center for Molecular Medicine and Immunology

People needed

18

Starts

1998-02-01

Last updated by the study team

2011-06-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Garden State Cancer Center — Belleville, New Jersey, United States
• St. Barnabas Medical Center — Livingston, New Jersey, United States
• St. Joseph's Hospital and Medical Center — Paterson, New Jersey, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.